CompletedPhase 2ACTRN12605000001695

A phase II trial of gemcitabine in a fixed dose rate infusion combined with cisplatin in patients with operable biliary tract carcinomas

A phase II trial of gemcitabine in a fixed dose rate infusion combined with cisplatin in patients with operable biliary tract carcinomas with the primary objective tumour response

Sponsor

AGITG/ NHMRC Clinical Trials Centre

Enrollment

45 participants

Start Date

Feb 1, 2005

Study Type

Interventional

Conditions

Adenocarcinoma of the gallbladder or intra/extrahepatic bile ducts

Eligibility

Sex: Both males and females

Plain Language Summary

Simplified for easier understanding

This study tests whether a combination of two chemotherapy drugs, gemcitabine and cisplatin, can help treat biliary tract cancer (cancer of the gallbladder or bile ducts). It is for people whose cancer has spread or come back and cannot be removed by surgery. Participation involves receiving these drugs through an IV infusion.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Gemcitabine delivered as fixed dose-rate infusion with cisplatin

Locations(1)

NSW,VIC,QLD,SA,WA,TAS, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000001695